Key facts
- Arsenal Medical’s last known valuation is $124.0M (Jun 2025).
- It has raised $46.8M across 4 recorded rounds; the latest was Early Stage VC ($6.0M) in May 2019.
- Notable investors include MedTech Innovator, Springboard Enterprises, National Institutes of Health, Polaris Partners, North Bridge Venture Partners — 7 tracked in total.
- Arsenal Medical has filed 18 Form Ds with the SEC since 2009, most recently Jun 2023 ($50.0M sold to 24 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Arsenal Medical
Funding rounds
4 roundsAbout Arsenal Medical
Developer of novel therapeutic in-situ forming materials designed to improve the clinical-stage drug delivery system. The company's products use safe, non-toxic, and biocompatible materials for therapy in intricate spaces without direct visualization, enabling healthcare professionals to provide local therapy for acute hemorrhage and other critical clinical conditions, including vascular injury and repair.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2005
- Employees
- 27
- Website
- arsenalmedical.com/
- Ownership
- Privately Held (backing)
Arsenal Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arsenal Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arsenal Medical in its N-PORT filings yet. We sweep new filings monthly.